Novak Jan, Reily Colin, Steers Nicholas J, Schumann Tillie, Rizk Dana V, Julian Bruce A, Kiryluk Krzysztof, Gharavi Ali G, Green Todd J
Department of Microbiology, University of Alabama at Birmingham, Birmingham, AL.
Department of Microbiology, University of Alabama at Birmingham, Birmingham, AL; Division of Nephrology, Department of Medicine, University of Alabama at Birmingham, Birmingham, AL.
Semin Nephrol. 2024 Sep;44(5):151565. doi: 10.1016/j.semnephrol.2025.151565. Epub 2025 Mar 13.
IgA nephropathy is a mesangioproliferative glomerular disease with significant morbidity and mortality. Most patients with IgA nephropathy develop kidney failure in their lifetime, reducing their life expectancy by a decade. Since its first description in 1968, it has been established that kidneys of IgA nephropathy patients are injured as "innocent bystanders" by nephritogenic IgA1-containing immune complexes. Results from clinical, biochemical, immunologic, and genetic studies suggest a multistep pathogenetic mechanism. In genetically predisposed individuals, this process results in formation of circulating immune complexes due to the binding of IgG/IgA autoantibodies to the polymeric IgA1 molecules with incomplete O-glycosylation. This event is followed by the addition of other proteins, such as complement C3, resulting in the formation of nephritogenic immune complexes. These complexes are not effectively removed from the circulation, and some of them pass through the fenestration of glomerular endothelial cells to enter the mesangial space and activate mesangial cells. It is thought that the process is initiated by soluble immune complexes and that their accumulation results in the formation of immunodeposits that further amplify glomerular injury. Here we summarize current understanding of the pathogenesis of IgA nephropathy and discuss experimental model systems that can inform development of new therapeutic strategies and targets.
IgA肾病是一种具有较高发病率和死亡率的系膜增生性肾小球疾病。大多数IgA肾病患者在其一生中会发展为肾衰竭,预期寿命缩短十年。自1968年首次被描述以来,已确定IgA肾病患者的肾脏是含有致肾炎IgA1的免疫复合物的“无辜旁观者”而受到损伤。临床、生化、免疫和遗传学研究结果提示了一种多步骤的发病机制。在具有遗传易感性的个体中,由于IgG/IgA自身抗体与O-糖基化不完全的聚合IgA1分子结合,这一过程导致循环免疫复合物的形成。此事件之后会添加其他蛋白质,如补体C3,从而导致致肾炎免疫复合物的形成。这些复合物不能有效地从循环中清除,其中一些会穿过肾小球内皮细胞的窗孔进入系膜间隙并激活系膜细胞。据认为,该过程由可溶性免疫复合物启动,其积累导致免疫沉积物的形成,进而进一步放大肾小球损伤。在此,我们总结了目前对IgA肾病发病机制的认识,并讨论了可为新治疗策略和靶点的开发提供信息的实验模型系统。